Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Receives Consensus Rating of “Hold” from Analysts

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) has been assigned a consensus rating of “Hold” from the eighteen research firms that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $24.3529.

Several research analysts have weighed in on the stock. Mizuho upped their target price on shares of Tandem Diabetes Care from $18.00 to $21.00 and gave the stock a “neutral” rating in a research report on Wednesday, December 17th. Sanford C. Bernstein restated a “market perform” rating and issued a $25.00 price target (up previously from $18.00) on shares of Tandem Diabetes Care in a report on Friday, January 9th. Stifel Nicolaus lifted their price objective on Tandem Diabetes Care from $16.00 to $20.00 and gave the stock a “hold” rating in a report on Wednesday, February 4th. Royal Bank Of Canada reiterated an “outperform” rating and set a $30.00 target price on shares of Tandem Diabetes Care in a research report on Wednesday, December 17th. Finally, Truist Financial set a $24.00 price target on Tandem Diabetes Care and gave the company a “hold” rating in a research report on Thursday, December 18th.

Institutional Trading of Tandem Diabetes Care

Large investors have recently modified their holdings of the business. Freestone Grove Partners LP acquired a new position in shares of Tandem Diabetes Care during the 3rd quarter worth approximately $22,706,000. Ophir Asset Management Pty Ltd purchased a new position in Tandem Diabetes Care during the second quarter worth $27,307,000. Assenagon Asset Management S.A. acquired a new position in shares of Tandem Diabetes Care in the fourth quarter worth $26,988,000. ArrowMark Colorado Holdings LLC lifted its position in shares of Tandem Diabetes Care by 36.7% in the third quarter. ArrowMark Colorado Holdings LLC now owns 3,691,198 shares of the medical device company’s stock valued at $44,811,000 after acquiring an additional 991,649 shares in the last quarter. Finally, Jennison Associates LLC lifted its position in shares of Tandem Diabetes Care by 42.3% in the fourth quarter. Jennison Associates LLC now owns 2,021,376 shares of the medical device company’s stock valued at $44,430,000 after acquiring an additional 601,260 shares in the last quarter.

Tandem Diabetes Care Price Performance

Tandem Diabetes Care stock opened at $18.89 on Thursday. The company has a market cap of $1.28 billion, a P/E ratio of -6.19 and a beta of 1.68. Tandem Diabetes Care has a one year low of $9.98 and a one year high of $36.58. The business has a fifty day moving average of $21.10 and a two-hundred day moving average of $16.80. The company has a debt-to-equity ratio of 2.33, a quick ratio of 1.90 and a current ratio of 2.44.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc (NASDAQ: TNDM), headquartered in San Diego, California, is a medical device company focused on the design, development and commercialization of innovative insulin delivery systems for people with insulin-dependent diabetes. Founded in 2006, the company introduced its first product, the t:slim® Insulin Pump, in 2011 and has since built a portfolio of next-generation pumps featuring touchscreen interfaces, remote software updates and integrated continuous glucose monitoring (CGM) capabilities.

The company’s flagship offering, the t:slim X2® Insulin Pump, is engineered to work with leading CGM sensors and features automated insulin delivery algorithms that adjust basal insulin rates based on real-time glucose trends.